STAMPEDE: Systemic Therapy in Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy - Androgen Suppression-Based Therapy Alone or Combined With Zoledronic Acid, Docetaxel, Prednisolone, Celecoxib, Abiraterone, Enzalutamide and/or Radiotherapy, Metformin and Transdermal Oestradiol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer

Trial Profile

STAMPEDE: Systemic Therapy in Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy - Androgen Suppression-Based Therapy Alone or Combined With Zoledronic Acid, Docetaxel, Prednisolone, Celecoxib, Abiraterone, Enzalutamide and/or Radiotherapy, Metformin and Transdermal Oestradiol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Abiraterone (Primary) ; Antiandrogens (Primary) ; Celecoxib (Primary) ; Docetaxel (Primary) ; Estradiol (Primary) ; Metformin (Primary) ; Prednisolone (Primary) ; Zoledronic acid (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STAMPEDE
  • Most Recent Events

    • 21 Sep 2017 Two new drugs has been added into the study. Hence treatment arms has been changed from 9 to 11.
    • 21 Sep 2017 Planned End Date changed from 31 Dec 2020 to 1 Sep 2024.
    • 21 Sep 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2024.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top